| Schedule of Segment Reporting Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Net product revenue |
|
$ |
42,805 |
|
|
$ |
100,779 |
|
|
$ |
79,055 |
|
|
$ |
187,472 |
|
Grant income |
|
|
950 |
|
|
|
226 |
|
|
|
1,928 |
|
|
|
226 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold |
|
|
23,673 |
|
|
|
27,630 |
|
|
|
49,445 |
|
|
|
51,353 |
|
Clinical expense |
|
|
8,737 |
|
|
|
3,954 |
|
|
|
13,799 |
|
|
|
7,981 |
|
Sales and marketing |
|
|
31,038 |
|
|
|
48,941 |
|
|
|
69,134 |
|
|
|
96,974 |
|
General and administrative |
|
|
22,497 |
|
|
|
24,028 |
|
|
|
43,879 |
|
|
|
47,662 |
|
Other segment items (a) |
|
|
54,077 |
|
|
|
5,844 |
|
|
|
54,149 |
|
|
|
11,963 |
|
Segment net loss |
|
|
(96,267 |
) |
|
|
(9,392 |
) |
|
|
(149,423 |
) |
|
|
(28,235 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of segment net loss: |
|
|
|
|
|
|
|
|
|
|
|
|
Reconciling items |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Consolidated net loss |
|
$ |
(96,267 |
) |
|
$ |
(9,392 |
) |
|
$ |
(149,423 |
) |
|
$ |
(28,235 |
) |
(a) Other segment items include: research and development related severance, salary, payroll taxes and benefits, research and development related rent and other facilities expense, research and development related depreciation and amortization, write-down to fair value for asset held for sale other income, net, and income tax benefit (expense).
|